India Ratings and Research has revised the outlook for the Company's bank loan facilities to Positive from Stable
Intimation of schedule for Virtual Investors Conference
Marksans Pharma Limited submits Transcripts of Investors/Analyst meet on Q4 FY 26 Audited Financial Results
Newspaper Publication regarding Second 100 day Campaign- "Saksham Niveshak"
Campaign for KYC and other related updations and shareholders engagement to prevent transfer of unclaimed dividend to IEPF
Press Release titled Marksans Pharma Ltd. to acquire 100 percent of Netherland based QliniQ B.V., strengthening presence in European Markets
Audio Recording of investor(s) / analyst(s) meet Conference Call on Q4 FY26 Financial Results
Newspaper publication of Audited Financial Results for the financial year ended 31 March, 2026
ASCR under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year 31, March 2026
The Board has recommended Dividend of Rs. 0.90 per share subject to approval of Shareholders at ensuing Annual General Meeting
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 500.03 | 531.24 | 586.13 | 560.01 | 590.62 | 641.92 | 681.85 | 70.85 | 619.99 | 720.41 | 754.43 | 856.11 |
| YOY Revenue Growth % | 15.28% | 17.38% | 22.15% | 15.23% | 18.12% | 20.84% | 16.33% | -87.35% | 4.97% | 12.23% | 10.64% | 1108.42% |
| Other Income | 10.10 | 19.00 | 4.80 | 16.53 | 14.95 | 11.06 | 27.85 | 1.65 | 5.64 | 21.57 | 20.14 | 35.17 |
| Total Income | 510.13 | 550.23 | 590.93 | 576.54 | 605.57 | 652.98 | 709.70 | 72.50 | 625.63 | 741.98 | 774.57 | 891.29 |
| Total Expenses + | 413.30 | 436.46 | 478.27 | 476.27 | 485.55 | 528.39 | 566.44 | 60.89 | 549.03 | 608.65 | 623.95 | 691.29 |
| Cost of Materials Consumed | 151.76 | 174.70 | 192.87 | 148.38 | 161.31 | 214.39 | 189.26 | 18.81 | 192.69 | 227.72 | 273.82 | 264.97 |
| Employee Benefit Expense | 68.24 | 71.13 | 74.53 | 79.75 | 80.48 | 84.16 | 88.44 | 9.72 | 98.39 | 103.80 | 111.99 | 106.76 |
| Other Expenses | 87.07 | 93.44 | 105.76 | 100.80 | 119.92 | 163.69 | 156.30 | 16.03 | 159.67 | 163.52 | 165.47 | 163.28 |
| Operating Profit | 86.73 | 94.77 | 107.86 | 83.75 | 105.07 | 113.54 | 115.41 | 9.96 | 70.96 | 111.76 | 130.48 | 164.82 |
| OPM % | 17.3% | 17.8% | 18.4% | 15% | 17.8% | 17.7% | 16.9% | 14.1% | 11.4% | 15.5% | 17.3% | 19.3% |
| Profit Before Tax + | 96.83 | 113.77 | 112.66 | 100.28 | 120.02 | 124.60 | 143.26 | 11.61 | 76.60 | 133.33 | 150.62 | 200.00 |
| Tax Expense | 26.39 | 29.92 | 29.69 | 22.63 | 30.95 | 26.84 | 38.19 | 2.54 | 18.40 | 34.20 | 36.93 | 50.97 |
| Tax % | 27.3% | 26.3% | 26.4% | 22.6% | 25.8% | 21.5% | 26.7% | 21.9% | 24% | 25.6% | 24.5% | 25.5% |
| Profit After Tax | 70.44 | 83.85 | 82.97 | 77.64 | 89.07 | 97.76 | 105.07 | 9.07 | 58.20 | 99.14 | 113.69 | 149.03 |
| EPS (Basic) | 1.52 | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 | 2.50 | 3.27 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,950.94 | 262.28 | 2,177.41 | 1,852.14 | 1,490.84 | 1,376.18 | 1,134.21 |
| YOY Revenue Growth % | 1025.09% | -87.95% | 17.56% | 24.23% | 8.33% | 21.33% | - |
| Other Income | 82.53 | 7.04 | 50.42 | 59.31 | 41.85 | 6.69 | 0.33 |
| Total Income | 3,033.47 | 269.32 | 2,227.83 | 1,911.45 | 1,532.69 | 1,382.88 | 1,134.54 |
| Total Expenses + | 2,472.92 | 218.93 | 1,804.30 | 1,573.80 | 1,285.18 | 1,080.71 | 768.41 |
| Cost of Materials Consumed | 959.21 | 75.30 | 667.70 | 612.97 | 540.67 | 419.76 | 371.33 |
| Employee Benefit Expense | 420.93 | 35.03 | 293.64 | 239.37 | 220.30 | 197.32 | 168.42 |
| Other Expenses | 651.95 | 60.02 | 387.07 | 352.09 | 294.84 | 244.20 | 228.66 |
| Operating Profit | 478.02 | 43.36 | 373.10 | 278.34 | 205.66 | 295.47 | 365.80 |
| OPM % | 16.2% | 16.5% | 17.1% | 15% | 13.8% | 21.5% | 32.3% |
| Profit Before Exceptional | 560.56 | 50.40 | 423.53 | 337.65 | 247.51 | 302.16 | 157.17 |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit Before Tax + | 560.56 | 50.40 | 423.53 | 337.65 | 247.51 | 302.16 | 157.17 |
| Tax Expense | 140.49 | 12.13 | 108.63 | 72.33 | 60.70 | 63.63 | 36.42 |
| Tax % | 25.1% | 24.1% | 25.6% | 21.4% | 24.5% | 21.1% | 23.2% |
| Profit After Tax | 420.06 | 38.26 | 314.90 | 265.32 | 186.81 | 238.54 | 120.75 |
| EPS (Basic) | 9.22 | 8.40 | 6.92 | 6.41 | 4.51 | 5.76 | 2.86 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Non-Current Assets + | 1,138.16 | 103.55 | 818.46 | 515.09 | 438.90 | 326.00 | 0.00 |
| Property, Plant & Equipment | 625.01 | 57.95 | 675.71 | 379.64 | 341.59 | 234.41 | 0.00 |
| Capital Work in Progress | 14.78 | 0.90 | 5.38 | 7.25 | 0.70 | 5.60 | 0.00 |
| Non-Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Goodwill | 45.26 | 4.09 | 39.50 | 38.49 | 30.03 | 0.00 | 0.00 |
| Other Intangible Assets | 72.97 | 36.16 | 60.73 | 68.17 | 56.69 | 74.96 | 0.00 |
| Current Assets + | 2,722.74 | 220.41 | 1,862.49 | 1,675.30 | 1,201.20 | 902.25 | 0.00 |
| Inventories | 972.28 | 84.55 | 617.94 | 484.74 | 424.44 | 404.32 | 0.00 |
| Trade Receivables | 644.57 | 54.00 | 453.18 | 416.85 | 394.78 | 271.38 | 0.00 |
| Cash and Cash Equivalents | 634.14 | 49.58 | 403.28 | 382.44 | 349.27 | 212.29 | 0.00 |
| Current Investments | 0.00 | 0.07 | 26.99 | 0.54 | 0.44 | 0.00 | 0.00 |
| LIABILITIES & EQUITY | |||||||
| Total Equity | 3,052.68 | 248.94 | 2,085.91 | 1,765.07 | 1,222.97 | 905.35 | 0.00 |
| Equity Share Capital | 45.32 | 4.53 | 45.32 | 45.32 | 40.93 | 40.93 | 0.00 |
| Other Equity | 2,977.84 | 242.16 | 2,019.74 | 1,699.85 | 1,161.34 | 845.56 | 0.00 |
| Non-Current Liabilities | 281.13 | 27.29 | 205.20 | 84.33 | 60.91 | 24.50 | 0.00 |
| Current Liabilities | 527.09 | 47.73 | 389.85 | 340.99 | 356.22 | 298.40 | 0.00 |
| Total Liabilities | 808.22 | 75.03 | 595.05 | 425.32 | 417.13 | 322.90 | 0.00 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activities | 458.13 | 20.67 | 230.41 | 237.41 | 99.26 | 178.74 | 0.00 |
| Cash from Investing Activities | -248.27 | -4.90 | -140.84 | -259.21 | -41.69 | -44.90 | 0.00 |
| Cash from Financing Activities | -70.93 | -6.51 | -68.73 | 197.83 | 79.51 | -15.29 | 0.00 |
| Net Increase/Decrease in Cash | 138.35 | 9.25 | 20.84 | 176.03 | 137.08 | 118.56 | 0.00 |